Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024523 (malabsorption)
 7,319 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

There is an increasing number of patients who have lad massive resection of the small intestine, and they pose a problem of how to readapt their nutrition. This has to take into account their malabsorption syndrome due to the extent and site of the resection. Other factors which may affect their nutritional status are whether the caecum has been left in place, the functional capacity of the remaining small intestine and the hepatic and pancreatic functions. This process of readaptation is luckily helped by the compensating hyperplasia of the remaining small intestine especially clearcut in the ileum. This organ and this process is closely related to the presence of food and biliary pancreatic secretions in the intestinal lumen. This is a strong argument in favour of early oral feeding of these patients. It should start two to three weeks after the operation with at the same time intravenous feeding being continued until such time as the intestine can adequately take over. Nevertheless at the beginning simple food is used, which can be absorbed directly (glucose, amino acids, medium chain triglycerides--MCT). These are given slowly and continuously by a silicon nasogastric tube. After some time when the patient has become used to this, he can be fed orally to a slightly greater extent, with the food divided into five or six meals.
 ...
PMID:[Significance and characteristics of enteral nutrition in massive intestinal resections]. 610 74

Since pharmaceuticals cannot be used in space until liver and kidney dysfunctions are corrected, and with invariable malabsorption, it appears there is no alternative other than to use subcutaneous magnesium (Mg) replacements in the presence of deficiencies and use of gene therapy. I suggest beginning with the correction of as many as four gene deficiencies: atrial natriuretic peptide (ANP), nitric oxide (NO), vascular endothelial growth factor (VEGF), and erythropoietin (EPO), all as well as Mg related to perfusion and angiogenesis. There is no evidence of significant lunar radiation levels in the absence of a solar storm. It could then be determined whether this has resulted in correction of liver and kidney dysfunction. If this persists, serial additions of gene therapy will be required determining the effect of each individual gene trial on organ function. Microgravity and endothelial gaps with leaks trigger reduced plasma volume. Partial correction by use of a plasma volume substitute and development of a delivery device may reduce complexity of gene therapy. Research would be conducted both on Earth and in microgravity, with the development of subcutaneous pharmaceuticals and Mg, and a space walk-reliable subcutaneous silicon device, given that no replenishable subcutaneous device is presently available. A three-pronged approach provides a plan for the next 50 years: A. complete correction of a Mg deficit; B. partial replacement with plasma volume substitutes, and C. multiple gene factor strategy.
 ...
PMID:Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years. 2169 38